Eloxx Pharmaceuticals Inc.
ELOX | NASDAQ
$13.45
+$0.27 (+2.05%)
At close: Oct 30, 2026, 4:00 PM ET
$13.79
+$0.34 (+2.53%)
Pre-market:
Nov 2, 2026, 7:12 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q1 2025 Mar 31, 2025 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 188K | 185K | 186K | 178K | 189K | 129K | 198K | 202K | 279K | 331K | 148K |
Gross Profit | n/a | n/a | n/a | -188K | -185K | -186K | -178K | -189K | -129K | -198K | -202K | -279K | -331K | -148K |
Operating Income | -4.45M | -3.8M | -1.22M | -3.64M | -4.14M | -5.48M | -6.03M | -7.14M | -10.3M | -10.95M | -11.63M | -10.25M | -13.06M | -8.41M |
Interest Income | 41K | 23K | 5K | 20K | 57K | 168K | 141K | 108K | 11K | 14K | n/a | 36K | n/a | n/a |
Pretax Income | -4.5M | -3.75M | -1.71M | -3.59M | -4.34M | -6.23M | -6.4M | -7.51M | -10.62M | -11.62M | -12.09M | -9.89M | -36.06M | -8.69M |
Net Income | -4.5M | -3.75M | -1.71M | -3.59M | -4.34M | -6.23M | -6.32M | -7.51M | -10.62M | -11.62M | -12.09M | -9.89M | -36.06M | -8.69M |
Selling & General & Admin | 1.61M | 2.14M | 712K | 2.2M | 1.62M | 1.81M | 2.55M | 2.07M | 2.52M | 2.86M | 3.52M | 4.76M | 7.02M | 4.19M |
Research & Development | 2.84M | 1.66M | 510K | 1.25M | 2.34M | 3.49M | 3.3M | 4.88M | 7.65M | 7.9M | 7.91M | 5.21M | 5.7M | 4.07M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.45M | 3.8M | 1.22M | 3.45M | 3.96M | 5.3M | 5.85M | 6.95M | 10.17M | 10.76M | 11.43M | 9.97M | 12.73M | 8.27M |
Interest Expense | 8K | 29K | 483K | 235K | 230K | 485K | 581K | 489K | 475K | 404K | 456K | 224K | 319K | 260K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.45M | 3.8M | 1.22M | 3.64M | 4.14M | 5.48M | 6.03M | 7.14M | 10.3M | 10.95M | 11.63M | 10.25M | 13.06M | 8.41M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | -77K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.79M | 4.38M | 345.92K | 249.79K | 201.12K | 196.94K | 196.94K | 196.95K | 196.94K | 196.93K | 196.33K | 195.93K | 150.89K | 91.32K |
Shares Outstanding (Diluted) | 6.79M | 4.38M | 345.92K | 249.79K | 201.12K | 196.94K | 196.94K | 196.95K | 196.94K | 196.93K | 196.33K | 195.93K | 150.89K | 91.32K |
EPS (Basic) | -0.66 | -0.86 | -4.95 | -14.38 | -21.58 | -31.63 | -32.09 | -38.12 | -53.91 | -59 | -61.58 | -50.45 | -238.98 | -95.21 |
EPS (Diluted) | -0.66 | -0.86 | -4.95 | -14.38 | -21.58 | -31.63 | -32.09 | -38.12 | -53.91 | -59 | -61.58 | -50.45 | -238.98 | -95.21 |
EBITDA | -4.45M | -3.73M | -1.23M | -3.17M | -3.93M | -5.56M | -5.64M | -6.83M | -10.01M | -11.02M | -11.43M | -9.38M | -35.41M | -8.27M |
EBIT | -4.45M | -3.73M | -1.23M | -3.36M | -4.11M | -5.75M | -5.82M | -7.02M | -10.14M | -11.22M | -11.63M | -9.66M | -35.74M | -8.41M |
Depreciation & Amortization | n/a | n/a | n/a | 188K | 185K | 186K | 178K | 189K | 129K | 198K | 202K | 279K | 331K | 148K |
Add to Watchlist
Select watchlists to add or remove ELOX